Skip to content
Natamycin
Natacyn (natamycin) is a small molecule pharmaceutical. Natamycin was first approved as Natacyn on 1982-01-01. It is used to treat aspergillosis, bacterial infections, blastomycosis, blepharitis, and candidiasis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
eye diseasesD005128
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Natacyn
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Natamycin
Tradename
Company
Number
Date
Products
NATACYNEyevanceN-050514 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
natacynNew Drug Application2021-11-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aspergillosisEFO_0007157D001228B44
bacterial infections—D001424A49
blastomycosisEFO_0007174D001759B40
blepharitisEFO_0009536D001762H01.0
candidiasis—D002177B37
coccidioidomycosisEFO_0007211D003047B38
conjunctivitis—D003231H10
cryptococcosisEFO_0007229D003453B45
fungal eye infections—D015821—
histoplasmosisEFO_0007310D006660B39
Show 5 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB10: Natamycin
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA03: Natamycin
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AA: Antifungal antibiotics, topical
— D01AA02: Natamycin
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AA: Antibiotics, gynecological
— G01AA02: Natamycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA10: Natamycin
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Corneal ulcerD003320H16.0——2——2
MycosesD009181B35-B49—11——1
Fungal eye infectionsD015821——1——1
Acanthamoeba keratitisD015823EFO_0007126——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNATAMYCIN
INNnatamycin
Description
Natamycin, also known as pimaricin, is an antifungal medication used to treat fungal infections around the eye. This includes infections of the eyelids, conjunctiva, and cornea. It is used as eyedrops. Natamycin is also used in the food industry as a preservative.
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
Identifiers
PDB—
CAS-ID7681-93-8
RxCUI7268
ChEMBL IDCHEMBL1200656
ChEBI ID—
PubChem CID5284447
DrugBankDB00826
UNII ID8O0C852CPO (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,168 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
114,495 adverse events reported
View more details